

Recent Advances in Nano-Formulations for Ophthalmic Drug Delivery

Sonia Dhiman, Govind Arora, Vanshika Rastogi, Thakur Gurjeet Singh*

Chitkara College of Pharmacy, Chitkara University, Punjab, India

Abstract:

Ophthalmic drug delivery based on nanotechnology is one of the technique which is used for delivery of medications for the ocular tissues to overcome different precorneal, dynamic and static ocular restrictions. In the previous decades, ophthalmic drug delivery research has focused on building up a novel, patient friendly and targeted delivery, which may out-perform the restrictions faced to medication levels of drugs in ocular tissues. Recent pharmaceutical techniques are seen by exploring new ways to make an effective delivery from regular topical formulations with saturation and viscosity enhancers. It includes development of conventional topical formulations such as suspensions, emulsions and ointments. Various nano-formulations have also been introduced for ocular drug delivery. Nano-technology based framework have been intended to guarantee low disturbance, satisfactory bioavailability and targeted drug delivery. This likewise enhances the rate of ophthalmic medication conveyance to a critical dimension. This review summarizes the role of nanoparticles eye drops in ocular drug delivery, and also puts a light on various kinds of penetration enhancers that have been used in eye drops so as to increase the penetration effect of the drug into the eye.

Keywords: Drug delivery systems; Eye drops; Nanotechnology; Nanoparticles; Ophthalmic formulations; Penetration enhancers

INTRODUCTION:

Researchers in last decade have been targeting to make an effective delivery for the use of ophthalmic drugs in the treatment of various infections and ailments. The methodology is being effectively explored with the assistance of nanomedicine application, through this methodology both the anterior as well as posterior section medicate conveyance are being targeted effectively. According to the innovation, it has gradually beaten the other conventional strategies that are utilized if there should be an occurrence of ophthalmic drug delivery. The nanotechnology based formulations helps to improve the bioavailability and ocular tissue compatibility and reduction in irritation. Various carriers like nanosuspensions, nano micelles, nanoparticles, dendrimers and liposomes have been evolved for ocular drug delivery. Number of interventions has successfully concluded that they can be made into application for an effective treatment for the ophthalmic drug delivery. But main aspects govern the bioavailability of the medications which may be physical or chemical. Nanoparticles (NP's) of size ranging from 10nm to 100nm are known to improve the topical passage of vast molecules that are poorly water soluble, through the barriers of the ocular system [1]. The benefits for using the nano-formulation is that it inhibits the cytotoxic behaviours and also improves the retention time of the drug in ophthalmic drug delivery profoundly enter into the more profound layer of aqueous humour and visual structure diminishing the precorneal loss of the medication by quick tear liquid turnover [2-3]. Many major ophthalmic disorders like glaucoma, corneal sickness, uveitis and retinal disease are affecting the public health. For an effective treatment for them the use of nano formulation for he same came into existence as we know

the nano formulation are site specific and also possess to have a better bioavailability. So this review will make you go through the summarised and well explained prospective of different penetration enhancers that have been utilized in eye drops to build the penetration impact of the medication into the eye.

Significant Role of Nanotechnology in Ocular Drug Delivery:

After all the basic efforts made by researcher's many interventions have proven to be effective hypothetically for the treatment of the disease. But many unknown ADE (Adverse Drug Effect) are to be noticed while implementing the intervention as a treatment. Basic example of ADE is the complexity of supplements for visual supplements accompanied with poor patient compliance. The studies performed suggested that an appropriate molecule measure with thin size range, guaranteeing low aggravation, adequate bioavailability as well as compatibility with ocular tissues should be required for every suspended drug in the field of ophthalmic drug delivery [5]. Some other aspects of formulation to be carefully considered are use of accurate buffering, wetting and suspending agents, preservatives, protective colloids and more. Hence, the most favorable ocular drug delivery can be one that causes less irritation, blurred vision and can be delivered in form of drops and require only one to two administrations per day [6]. Although topically delivered drug easily reaches the anterior segment of the eye, but a very little portion of it reaches the posterior segment. This calls for various drugs like corticosteroids, antiglaucoma drugs and some anti-toxins to be controlled by fundamental course. However, no part of the dose touches the ocular tissues, following

fundamental organization. Remedially powerful doses by means of this course, may cause an incredible number of size impacts. Various solvency related issues of inadequately solvent medications, as budesonide, ganciclovir, dexamethasone, and so forth have been explained because of the utilization of nanotechnology-based medication conveyance frameworks, for example, SLP (Solid Lipid nanoparticles), LP (Liposomes) and Nanosus (Nanosuspension) [7]. Effective methodology can be studied to mainly deal through the medication in order to allow provincial explicit conveyance and lessen symptoms in different organs [8]. Depending upon the surface properties, relative hydrophobicity and particle charge, nanoparticles can be viewed as viably utilized in conquering the retinal boundaries. Besides, frameworks, for example, liposomes, nanospheres, and so forth typifying the medications can likewise offer insurance to the medication and along these lines upgrade presentation of medication by controlled release [7]. Different film hindrances, for instance blood retinal boundary in the eye can likewise be effectively crossed by nanotechnology-based medication conveyance [9,10]. Nanotechnology-based medication conveyance frameworks may affirm to be the astounding medication conveyance devices if there should be an occurrence of some ceaseless visual illnesses requiring customary medication organization, for example, incessant cytomegalovirus retinitis (CMV). For the disease of this class the drugs are generally preferred to be delivered through intravenous (i.v) route of administration over topical delivery best example we can quote can be of ganciclovir (GCV) as its main concern in delivering the drug through i.v is the half-life of the drug, as to maintain its concentration you need to administer drug with multiple injections, as the drug prevents the viral deoxy ribonucleic acid (DNA) from replicating, but does not eradicate the virus from the tissue. As a result, therapy has to be continued for a long time period, the end results of which might be retinal detachment, endophthalmitis and even cataract development [11]. GCV intravitreal implants may also be used which would help the release of drug for a continuous period of six to eight months, but on the other hand some ADR (Adverse drug reaction) or ADE(Adverse Drug Effect) could be experienced which may include vitreous haemorrhage, astigmatism; requirement of surgery for removal of the implants, restricts their use[12-18]. Keeping all the challenges in consideration researchers have found that its way better to use natural polymer nanoparticles as it enhances the formulation in many ways one of which the most important is the sustain release. The best thing about these nanoparticles is that they don't have a cytotoxic behaviour over ophthalmic delivery. neither these nanoparticles stimulate the reactions that are inflammatory in the retinal tissue, nor do they disturb the environment of the surrounding ocular tissues [19].

Drug Delivery through Different Nanomedicine Systems:

From many years production of various nano particulate drug delivery systems are being manufactured such as

nano-emulsions, nanoparticles, dendrimers, nanosuspensions, cyclodextrins, niosome, liposomes, etc. Main motive of all these efforts is to mainly improve the ophthalmic drug delivery to a significant level as explained in **FIGURE 1**.




Figure 1. Various nanoparticulate drug delivery systems.

Microemulsions:

Microemulsions can also be defined as water and dispersions of oil that requires surfactant and co-surfactant agents for stabilizing the interfacial area. Microemulsions, due to their definite structures and basic properties, such as stability, easy sterilization, easy preparation through emulsification and high capacity for dissolution of drugs; can be an interesting alternative to topical ocular drug delivery [20]. The presence of surfactants and co-surfactants in oil-in-water microemulsions could expand the take-up of the medication by expanding the membrane permeability. Here, these systems work as penetration enhancers for facilitating the corneal drug delivery [21]. Furthermore, microemulsions as compared to the native drug, attains higher penetration into more profound layers of aqueous humor and ocular structure as well as sustained release of medication instilled to cornea. Some of the major advantages imparted by using this delivery system can be discussed which mainly include enhanced properties as absorption promoters, less viscosity and greater ability as medication delivery vehicles [20].

Nanosuspensions:

Nanosuspensions are mainly formulated for the medication which has a weak solubility profile in the suspended appropriate scattering medium. Polymeric nanoparticles suspension (PNS) has an ability to provide us fundamental increase in the bioavailability giving the formulation a good edge in the kinetic profile of the formulation. As the use of PNS also help us to have no alteration in aggravation of iris, conjunctiva or cornea by

the use of ophthalmic formulation. The presence of good positive charge helps it to have improved grip over the corneal surface [22].

Nanoparticles:

Nanoparticles are said to be the particles containing a diameter less than 1mm, including an assortment of biodegradable materials, similar to synthetic or natural polymers, metals just as phospholipids. Drug may be attached to the surface or integrated in the matrix. Nanoparticles that are made up of a range of natural polymers like gelatin, chitosan, albumin, sodium alginate and biodegradable polymers such as polycyanoacrylate, polylactides (PLAs) and poly (D,L-lactides) can be used well for an efficient delivery of drugs to the ocular tissues. Nanoparticulate drug delivery has shown to have positive results in ophthalmic drug delivery over a decade. Studies shows that nanoparticles having dissimilar electric charge and size, on injecting into the vitreous, travel through the retinal layers and result in accumulation of the retinal pigment epithelium (RPE) cells. Nanoparticles that are present in RPE cells for a significant time of 4 months After a periodic administration of the injection through I.V injection it is taken under observation [23]. Drug loading plays a very important role in the medication as it should be well contrasted with the entrapment ratios of the drug through the nanoparticles, as the charge ratio should be appropriate one for a proper drug delivery. Li et al. [24] According to the study by. Li et al. there was no proper distribution rate of the progesterone drug, and further the problem of distribution occurred due to strong molecular interaction between polymer and drug. However, it was totally exemplified in polybutyl cyano-acrylate nanospheres. Some studies prove that nanoparticle mediation can be a great medication conveyance delivery system for a specific drug being used for the treatment of specific disease and the best example of it can be seen in CMV retinitis, as they contain nonantigenic properties and are non-lethal and biodegradable. Positively charged GCV and oligonucleotide account to a enhanced absorption property with the help of high charged amino acid substances [19]. With the help of natural polymer interaction in the ocular drug delivery have shown to be very effective in penetrating conjunctival and corneal surface.

Liposomes:

Liposomes are known as to be the tiny sized artificial vesicles which may be framed from non-harmful cholesterol and phospholipids. The charge on the surface of the liposomes is an important reason for its role as an ocular drug delivery system. Preferentially, positively charged liposomes are captured at the negatively charged surface of the cornea, as compared to negatively or neutrally charged liposomes. The attraction for binding between the liposome and corneal surface suggests that their interaction in nature is electrostatic, being greatest for positively charged, less for negatively and least for the neutral ones. Liposomes help in directly transferring the

drug from liposomal to epithelial cell membranes, enhancing the corneal penetration of drug by absorbing on the corneal surface. Phosphodiester 16-mer oligothymidylate (pdT16) oligonucleotides encapsulated liposomes administration has shown to be very effective to release and discharge drug into retina, choroid and vitreous of the eye. This medication mainly is not focused over tissues and the distribution is appropriate [25]. Moreover, the liposomes also provide shielding effect over degradation of drug nanoparticles. After all these outcomes and delivery systems still have some of the factors affecting the drug delivery of great concern: restricted medication capability, short shelf life, sterilization issues and uneven conditions for preparation.

Niosomes

Niosome have proven to be a very effective carrier for the delivery of the drugs having lipophilic and hydrophilic due to their good entrapment values. In the progressing era a drift has been noticed over the use of niosome over the conventional i.v drug delivery. The reason of the shift is said to be because of some factors. The reason of choosing niosome drug delivery over the i.v drug delivery was to overcome the challenges being faced for drug delivery. Molecular toxicity and enhanced drug molecule stability are the major challenges which are well overtaken with the use of niosome. It also takes care of the entrapment values of the drug that may be hydrophilic also as lipophilic drugs, no exceptional conditions and preventive measures for treatment of the surfactants. It also imparts controlled delivery at centered area by not affecting biocompatibility, their non-immunogenic and biodegradable nature [26]. As all these years have passed niosome have proven to be an effective delivery system for the ophthalmic drugdelivery. just in case of ocular drug delivery, they need advantage i.e. as a result of their larger size, they are doing not drain into the general pool; even their disc kind offers a much better slot in the cul-de-sac of the attention [27,28].

Dendrimers:

Macromolecular mixes mainly consisting of chain branches surrounding the inner core are classified mainly as the dendrimers. Because of their ease of functionalization and preparation, nanometer size range, as well as their capability to exhibit a number of copies of surface groups for various biological processes, they are known to be attractive systems for the drug delivery [29-31]. Drug delivery for specific ophthalmic drug delivery can be effectively enhanced by using dendrimers. Many studies have been undertaken with the use of bio adhesive polymers for example poly (acrylic) acids. Condensing the effective drug release over the retaining are with a contact and also increasing the residence time and diminishing the recurrence of dose, Patton et al., 1995 stated that the dendrimers are the best option if we need the desired results. [32].

Cyclodextrins

CDs (Cyclodextrin) have proven to be very effective for making inclusion complex for effective medication for a

specific disease [33]. After all the efforts, it has been concluded that it is the most effective way for the ophthalmic drug delivery. As it surpasses some of the major factors which may modulate the drug's kinetic profile which indeed imparts benefits like boost ocular absorption, corneal penetration and viability of ineffectively water-soluble drugs like acetazolamide, dexamethasone and cyclosporine, etc. As CDs are making a good impact for the ophthalmic drug delivery so they are being widely explored for bioavailability and dependability of ophthalmic medication [33]. The fundamental application which makes the CDs progressively ideal for the utilization in ophthalmic prescription is the primary factor of medications. Despite the CDs do enter other tissues outside the eyes subsequently, but the drug is completely harmless. This mainly happens while using the CDs for the delivery of drug to conjunctiva, cornea, sclera [35].

Nanomedicine Aided Contact Lenses:

Topical application of ophthalmic drugs in form of eye drops can also be given by using contact lenses loaded with nanoparticles. The increase in the residence time of the drug molecule in post lens tear film has been seen in

case of lens, compared to the topical application of drugs in form of eye drops [6, 36]. The increased residence time allows the drug to permeate through cornea and decreases the drug absorption into the blood stream through nasolacrimal duct or conjunctiva. Keeping in mind the drug molecule diffusion property matrix particles are loaded over the contact lenses to provide continuous release. The major setback with the use of loaded contact lenses is that it only provides drug release only for few hours with some specific drugs. Equilibrium solubility of the drug is the major factor which is the major challenge while using the nanoparticle loaded lenses. It is the major factor because it mainly governs the number of drugs which is able to be loaded within the lens matrix that's sometimes little for many of the medicine as if this factor is not considered the lens can take hours for absorption through diffusion. Now the only solution which researchers have found for an effective method is that modified nano delivery systems like microemulsions, or vesicles like liposomes, the release time of the movement of medication from the contact lenses can be taken in consideration.

Nanoparticles	Properties
i) Solid Lipid Nanoparticles (SLNs)	<ol style="list-style-type: none"> 1. Ability to produce particles with small size. 2. Have adequate loading capacity for hydrophilic as well as lipophilic drugs. 3. On long storage basis, they are stable in aqueous dispersions. 4. No toxic residues are left behind from the production process. 5. They are biodegradable in nature.
ii) Fullerenes	<ol style="list-style-type: none"> 1. 12 Pentagonal rings are enough to result in closure of cage. 2. In diameter, Fullerenes cages are almost 7-15 Å and their thickness is almost equal to one carbon atom. 3. Of the all known structures, they have the highest packing density. 4. Very stable from chemical as well as physical point of view. 5. Maximum tensile strength of any known 2D element.
iii) Liposomes	<ol style="list-style-type: none"> 1. The bioavailability to target cells in circulation is improved by change in pharmacokinetics for the liposomal drugs. 2. Improved solubility of amphiphilic and lipophilic drugs. 3. Passive targeting to the cells of the mononuclear phagocytic system. 4. Improved transfer of charged, hydrophilic molecules. 5. Sustained release system of locally or systemically administered liposomes.
iv) Nanostructured Lipid carriers (NLCs)	<ol style="list-style-type: none"> 1. Drug flux through the skin is enhanced by small size of lipid particles. 2. Carriers are made of biological and physiological lipids. 3. These carriers allow for the controlled release of the drug. 4. They show low cytotoxicity and low systemic toxicity.
v) Nano shells	<ol style="list-style-type: none"> 1. Non-invasive treatment can be done by NIR light 2. Identical Nano shells can be used to diagnose and treat cancer. 3. Reflection is used to identify Nano shells. 4. By heating of Nano shells, cancer cells can be destroyed.
vi) Super paramagnetic Nanoparticles	<ol style="list-style-type: none"> 1. Efficient design of targeted drug delivery systems requires decoration of the surface of magnetic nanoparticles where the targeting moieties are covered on surface of the SPIONs. 2. Improper surface chemistry of nanoparticles has ability to be strictly covered by the proteins which can effect the elimination of targeting moieties. 3. SPIONs can be coated in situ during the growth and nucleation of the magnetic core.
vii) Dendrimers	<ol style="list-style-type: none"> 1. When compared to traditional linear polymers, they have better chemical and physical properties. 2. They have well defined monodisperse macromolecules & a uniform molecular weight. 3. Nanoscale objects with a surface and interior. 4. Large dendrimers don't have a CMC but can host a small molecule. 5. Nature of surface groups strongly affects the reactivity and solubility of dendrimers.

Table 1. Various nanoparticles and their properties.

Nanoparticles in Eye Drops:

For ages the conventional treatment for the ocular disease is being done with help of the eye drops, but the main concern's which hinders the treatment with help of eye drops are quick elimination, enzymatic medicament debasement, physiological hindrances and protein authoritative. According to the methodology, it effects the drug pharmacokinetic profile in terms of bioavailability and ocular residence. The fact which can never be waved off is that the conventional eye drop rate of absorption lies between 3-5% of the given medication, as the rest goes towards the opposite side and results in outside flow the drug. This outside flow makes the drug flow to the nasolacrimal tube. Permeability obstructions in the epithelium on the outside of the eye and rapid exchange of tear fluid are main reasons for poor bioavailability [37]. Due to tear flow, the drug is washed into nasolacrimal duct and some part of the drug in the eye drop may reach the systemic circulation, having a risk of systemic side-effects. Other result of poor bioavailability in case of topical eye drops is that repetitive dosing may be required to achieve the desired clinical effect [38]. Nanoparticles have appeared to assist effectively the ocular medication delivery against the particular infection treatment [39]. Nanoparticles are equipped for conveying medication to focused space and regulate the pharmacokinetic profile of varied bioactive compounds. Various characteristic polymers like alginate, gelatin, chitosan, and so on and biodegradable polymers, for example, poly (ethylene glycol) (PEG), poly (lactic-glycolic corrosive), lactic corrosive, alkyl cyanoacrylate and acrylic corrosive of poly family were used to assist the ophthalmic formulation of nanoparticles for the need to modify so major factors like the drug release profile and physiochemical properties of the medication being conveyed to the particular site. Cationic solid lipid nanoparticles (cSLN) has made a great impact in improving the ocular hypotension impact of melatonin (MEL) by making an effective lipid work in existence of softisan 100 which plays a significant role in formulation accompanied by the nearness lipid modifiers like stearic (SA) or palmitic acid (PA) [40]. Softisan 100 joined with the varying percentage of cationic lipid didecylidimethyl ammonium bromide (DDAB), to accomplish the favored nanoparticle surface charge. So, the main pharmacological intervention by this method was seen to be the decrease of intraocular pressure (IOP) making it to prolong 24 hrs. To enhance the viability of the melatonin in decreasing intraocular pressure, NP formulation of melatonin was used to have a great effect over the ocular delivery.

Dexamethasone nanoparticles (DSP-NP) which is a potent corticosteroid by nature assisted with loaded nanoparticles formulation which are of natural origin and are easily degradable, for instance, Poly (lactic-co-glycolic acid) (PLGA) serves to anticipates corneal graft dismissal once surgery is successful [41]. Keeping all the factors in mind Sustained release of dexamethasone sodium phosphate (DSP-NP) nanoparticles is probably going to result in gradual degradation of Poly (lactic-co-glycolic acid) and diffusion of dexamethasone through the PLGA matrix.

DSP-NP showed higher drug retention compared to conventional DSP when administered in conjunctiva. DSP-NP helps to achieve consistent level of drug within the aqueous humour when administered. DSP-NP (200 nm) provides sustained drug unleash over fifteen days in vitro below sink conditions, provided sustained ocular drug levels for a minimum of for one week after subconjunctival administration, and helps to stop corneal graft rejection and inflammation.

Poly(lactide-co-glycolide) assisted nanoparticles loaded with cyclosporine A (CyA) were made in the laboratory by using the oil in water emulsification dissolvable evaporation methodology. CyA had been used for ages for treating infections and various eye ailment [42]. Nanoparticles used were scattered in the range of 150 to 300 nm which was dependent over the planning factor. The nanoparticles also possessed a zeta potential which was towards the negative scale of - 16 to - 35mV which gave us a definite factor that drug would be released in 24 hrs causing no toxicity factors. Cryoprotectants like trehalose and carnitine were included in ophthalmic formulations for securing against ocular surface issue, for example, dry eye disorder with adjusting the measure of Nano detailing utilized for ophthalmic medication conveyance.

Cataract surgery, uveitis and muscular edema have been potentially treated for ages with DEX (dexamethasone). It mainly acts for reducing the inflammation been produced in the body after the surgery by inhibiting formation and release of various inflammatory cytokines. Blended Nano micellar definition (MNF) of dexamethasone was formulated by utilizing polymers like D- α -tocopherol polyethylene glycol-1000 succinate etc. A central composite design was applied to optimize the formulation based on their size, entrapment efficiency and polydispersity index. A specific proportion of Vit E TPGS and Oc-40 (4.5:2.0) at a particular weight percentage ratio produced excellent loading, drug entrapment, small mixed Nano micellar size. Solubility of DEX in MNF was improved by many folds as contrast to normal aqueous solubility and its entrapment efficiency. It was dependent on two input factors that is Vit E TPGS and Oc-40 [43]. Glaucoma is amongst the foremost continuous reasons for visual incapacity and visual impairment for the duration of the world and is more and more normal within the older population. exaggerated intraocular weight (IOP) assumed a clear job in eye disease that will hurt the ciliary corridor and optic nerve within the focal visual zones. In ocular weight and organization time for the medication like concerns can be overcome by the use of nanoparticles of DSF (disulfiram). The formulation was made with the methodology of bead mill method. High stability in the formulation could be due to scattered DSF nano particles. Which neither or less imparted good anti-microbial activity. Due to the methodology used for preparation; the pressure applied from it made an impact over the drug profile. It also contained polymers like methylcellulose, BAC (benzalkonium chloride) and diuretic drug. The dispersions containing disulfiram nanoparticles provide novel potential to adequately treat eye disease.

Potent drug like prednisolone is mainly used for treating ocular inflammation in the form of loaded nano capsules. Polymers are mainly used for assisting the formation of loaded nanoparticles to prompt the ideal molecule size for e.g. caprolactone or Eudragit RS100. Molecule size controlled by laser diffractometry and nanoparticle trailing investigation [45]. Nano capsules formulation of prednisolone showed size in range of 100 to 300 nm with encapsulation efficiency of 50% after 5 hr. Potential use of Nano capsules as suitable ocular nanodevices has been confirmed by the lack of ocular cytotoxicity and irritancy. Cyclodextrin based nanogels of dexamethasone as eye drops are well tolerated with no irritation, redness or other toxic impacts [46]. The nanogel was prepared by emulsion-solvent evaporation technique with simultaneous cross-linking. This resulted in consistent dexamethasone fixation for 6 h in the aqueous humor. The Cyclodextrin based nanogels formulation contained 25-times more medication than conventional formulation and furthermore demonstrated a delayed and steady convergence of dexamethasone on the eye surface, enhances the ocular bioavailability.

Indomethacin is a potent drug and widely used drug for the treatment of ocular aggravation. Indomethacin belongs to the class of anti-inflammatory category chiefly used in the ocular aggravation. A particular formulation containing indomethacin were made containing zirconia beads, Bead Smash 12 with 0.5% Indomethacin nanoparticles diminishes the corneal lethality of conventional. Indomethacin eye drops updates its corneal porousness [47]. Thus, it was absolutely found that the indomethacin nanoparticles containing beads effectively consolidates the extension of zirconia beads to the indomethacin microparticles containing benzalkonium chloride, mannitol or Methyl cellulose and leading to the effective ocular treatment over conventional eye drops.

Tranilast is anti-allergic and anti-fibrotic drug that suppress the collagen synthesis, inhibits matrix metalloproteases and suppress the monocyte/macrophage infiltration in inflammation. helps to formulate ophthalmic formulation for ocular inflammation with enhanced permeability and less corneal toxicity [48]. Ophthalmic drug delivery system using Tranilast nanoparticles are also expected to bring about improvements in side effects.

Natamycin being a potent drug for the treatment of mycotic keratitis. poly-D-glucosamine and polycaprolactone nanoparticles are mainly responsible for the targeted delivery of the nanoparticles. Nanoparticles consist of hydrolysable dye (200 nm molecule diameter) arranged utilizing reprecipitation technique, achieves a more noteworthy (around 50-fold) ocular penetration of eye drops than that of micron-sized particles [50]. Additionally, the γ -cyclodextrin dexamethasone nanoparticle and dorzolamide nanoparticles drops have a progressively supported impact and high intervention obsession outside the eye [51].

Sunna Jóhannsdóttir .et al performed the study to develop surfactant free aqueous 0.05% (w/v) Cyclosporin A (CyA) eye drops where the drug present in an aqueous vehicle contained Cyclosporin A / cyclodextrin (CyA/CD)

nanoparticles [52]. They showed that addition of different types of cyclodextrin helps to enhance the solubility and formation of nanoparticles in cyclosporin eye drops. Others polymers like polyvinyl alcohol, benzalkonium chloride, disodium edentate have positive effect on the complex aggregation. They have not shown any effect on the cyclodextrin solubilization of the drug. These polymers help to form successful semi-solid eye preparations. For ophthalmic use diclofenac sodium preparations were stacked with N-trimethyl chitosan nanoparticles (DC-TMCNs), which caused improvement in ocular bioavailability while comparing it with regular diclofenac sodium eye drops for treating ophthalmic irritation treatment. By utilizing ionic gelation methodology, the meaning of DC-TMCNs was being set up. The altered detailing incorporates N-Trimethyl chitosan (TMC), diclofenac sodium and sodium tripolyphosphate in the weight extent of 3:1:1. The expansion in N-Trimethyl chitosan compound prompted exponential growth in molecule size, zeta potential and medication entrapment value effectiveness of diclofenac sodium stacked in N-Trimethyl chitosan nanoparticles. In situ gel formation improves the issue of quick disposal of ophthalmic arrangements after instillation and however it keeps up an adequate concentration of medication in pre-corneal region.

The treatment of conjunctivitis, keratitis and Kerato conjunctivitis was done using Moxifloxacin. For the formation of nanoparticles of moxifloxacin Ion sensitive polymer gellan gum was used by the method solvent evaporation. In the presence of cations formulation of moxifloxacin formed gel and sustained drug release over a period of 12 h was shown. Although, *in situ* gel formation can be used for ophthalmic drug delivery in the modified approach of nanoparticles. [54].

Small liposomes in eye drops were produced by micro fluidization resulting in an attractive option for drug delivery to the eyes posterior segment tissues. Micro fluidizing process helps for the formation of small size liposomal drug delivery system for ophthalmic formulation. These liposomes are physically stable for prolonged period of time [55]. Transferrin was used as a targeting ligand for direct delivery of drug to retinal pigment epithelium. Varying size of Liposomes helps to distribute drug to the retinal pigment epithelium (80nm) and choroidal endothelium (100nm). Ligand based targeted drug delivery systems with liposomes helps for the treatment of retinal diseases.

Extensive use of Curcumin-loaded albumin nanoparticles (Cur-BSA-NPs-Gel) gel system for ophthalmic delivery system with extended resident time and upgraded ocular bioavailability. [56]. By the use of desolvation method Albumin nanoparticles were set up and formation of gel by cold method took place. Depending upon the presence of polymers such as Pluronic F127 and Pluronic F68 the nanoparticles indicated the temperature – responsive features. Thus, causes increase in curcumin bioavailability in the aqueous humor. These polymers are used in the formulation with a basic reason to modify the drug conveyance to the ocular treatment. Dorzolamide g-

cyclodextrin nanoparticle eye drops are locally not much toxic or irritating to the eye [57].

Ophthalmic formulations together with brimonidine-loaded bio adhesive cationic chitosan or anionic alginate nanoparticles (NPs) offer upgrade in topical ocular brimonidine conveyance that gave extended intraocular weight (IOP) reduction and after may be used for entire treatment of glaucoma [58]. Brimonidine-stacked chitosan (CS) or atomic number 11 alginate (ALG) nanoparticles created by a spontaneous emulsification solvent diffusion methodology. Therefore, each cationic and anionic polymer chitosan and alginates possess totally different properties that are answerable for their superiority and their penetration enhancing impact. The optimized NP formulations had the fascinating particle sizes, zeta potential, and surface morphology. The prepared formulation decreases the IOP for quite twenty-five hours

when once topically applied. Sparfloxacin is used against many of the ocular pathogens, which are responsible for conjunctivitis, blepharitis and corneal ulcers. Sparfloxacin nanoparticle formulation has been shown to remain at corneal surface for longer duration with reduced clearing time [59]. Nanoprecipitation technique was applied to make the pefloxacin nanoparticles. Poly lactic co glycolic corrosive (PLGA) nanoparticles, are preferred due to their some distinctive feature like their smaller size, can provide extended retention time on the eye as compare to conventional formulation. Keeping in mind the adequacy of the formulation it was really important for the formulation to add in cationic which aided in maintenance of nanoparticles on the eye. All the nanoparticles used potentially are summed up in the **Table 2** below and are briefly explained also,

S. No	Drug	Polymers	Administration	Inferences	Reference
1.	Pilocarpine nitrate	Liquid crystal nanoparticles	Eye drops	Increased Permeation. Prolonged Drug effect. Allows sustained release of the drug.	[60].
2.	Riboflavin	Complex formation of Hydrogen-bonded interpolymer between poly(carboxylic acids) and methylcellulose (MC)	Eye drops	Good adhesiveness. Enhanced retention time.	[61].
3.	Rosmarinic acid	Chitosan	Eye drops	Enhanced retention time. Enhanced Mucoadhesive properties.	[62].
4.	Brimonidine	Poly-caprolactone .Poly(L-lactide), Poly(D,L-lactide-co-glycolide).	Eye drops	Allows sustained release of the drug.	[63].
5.	Tetrandrine	Solid lipid nanoparticles (SLNs)	Eye drops	Enhanced medication release. Enhance the bioavailability. Improved therapeutic efficacy.	[64].
6.	Celecoxib	Polycaprolacton, poly(L-lactide) and poly(D,L-lactide-co-glycolide)	Eye drops	Allows sustained release of the drug without any burst effect.	[65].
7.	Ciprofloxacin hydrochloride	Chitosan (CS)-coated liposomes	Eye drops	Enhanced ocular bioavailability. Higher retention of drug.	[66].
8.	Cyclosporin A	Methoxy poly (ethylene glycol)-hexylsubstituted poly (lactides)	Eye drops	The drug dose will be simply adjusted for the treatment of specific diseases, such as dry eye syndrome, autoimmune uveitis, or the prevention of corneal transplant rejection. Drug bioavailability may be increased.	[67].
9.	Gatifloxacin	Solid lipid nanoparticle	Eye drops	Enhanced ocular bioavailability. Prolonged residence time.	[68].
10.	Terbinafine hydrochloride	Chitosan	Eye drops	Increased ocular bioavailability. Drug penetration enhanced.	[69].
11.	Levofloxacin	Tween 80	Eye drops	Biphasic release pattern with burst release with respect to initial phase which is followed by sustained release. Antibacterial activity like marketed eye drops.	[70].
12.	Dexamethasone	N-isopropylacrylamide (NIPAAm), Vinyl pyrrolidone (VP), and Methacrylate (MAA)	Eye drops	Rapid treatment as compared to other nano formulations. Higher anti-inflammatory activity for long duration. Less side effects.	[71].
13.	Fluorouracil (5FU)	Chitosan coated sodium alginate-chitosan nanoparticles	Eye drops	Allows for sustained release of the drug. Enhanced bioavailability.	[72].
14.	Timolol	Polyhydroxy ethyl methacrylate	Eye drops	Long lasting drug release.	[73].

Table 2. Various nanoparticles used in eye drop formulation.

ROLE OF PENETRATION ENHANCERS IN OPHTHALMIC DROPS.

The most important step that has been explored to upgrade the bioavailability of the ocular drugs is by improvement in retention time [74] of the specific formulation by adding the penetration enhancers and mucoadhesive polymers in the formulation which results in the enhancement of the retention time. In general, nanoparticles applied topically have served as an approachable method for the ocular drug delivery as it also helps in the improvement of the precorneal retention time [76,77]. For instance, Mucoadhesive polymeric NPs such as dextran-chitosan, hyaluronan-chitosan, chitosan, poly(hexyl cyanoacrylate) have shown to increase the retention time of the drug carrier in conjunctiva and cornea[78-80]. Moreover, it has been seen that Pluronic F68 and chitosan themselves can also perform as penetration enhancers[81-83]. Depending on their mode of action, penetration enhancers improve/increase the permeability of the drug molecules in sclera, conjunctiva, cornea[84,85]. The best example which can be seen over medication are the penetration enhancer like benzalkonium chloride acts by breaking down the anatomical and physiological diffusion barriers for solvent and substance molecules found on the external layer of epithelial tissues [86]. On the substitute perspective, an unsaturated fat known as capric acid, binds to the polar head get-together of plasma film and constructs the perviousness of the medication atoms [87]. Ethylenediamine-tetra-acetic acid (EDTA) is another entrance consideration that plays out its movement by complexation with Ca²⁺ particles and adjusts the tight crossing points of epithelial cells. it'll even reversibly disturb the plasma film [88,89]. sodium taurocholate and sodium Glycocholate are the stomach related juice salts that improves the penetrability of film layer by disturbing the cell-cell intersection and separating the discharge, of medications through the paracellular course.

SAFETY/TOXICITY OF NANOPARTICLES IN THE EYE

The safety of PCEP (poly {(cholesteryl oxocarbonylamido ethyl) methyl bis(ethylene) ammonium iodide] ethyl phosphate}), magneticnanoparticles and chitosan, have been examined as ocular gene delivery vehicles [90]. Their toxicity was tested in Dutch Belted rabbits for subretinal delivery and New Zealand white rabbits for intravitreal delivery. The evaluation depended on retinal degeneration, inflammation and retinal histopathology for a time-period of 7 days. Intravitreal delivery of chitosan nanoparticles resulted in associate inflammatory response, at concentrations required to deliver 1 µg of deoxyribose nucleic acid (DNA) within the nanoparticle form. Both, upon subretinal and intravitreal administration, magnetic nanoparticles and PCEP neither resulted in inflammation nor retinal pathology.

The safety concern of the nanoparticles against the pathological condition as its bio distribution is the main factors. Recent studies about the PAMAM dendrimers have appeared to show significant effect over the healthy

eye through the intravitreal administration. At last with help of the extensive research it was found that with the help of PAMAM dendrimers there was a significant effect over the healthy eye through the intravitreal administration. As a result, the retention over the retina was effective for the treatment of retinal degeneration [91]. Researchers have observed that periodic i.v administration of lipophilic amino acid in combination to VEGF oligonucleotide (ODN-1) the main purpose of administration is to restrain laser-induced choroidal neovascularization. But noticed that it tends to show a well toleration of Dendrimer-ODN-1 it also increases the inflammation related antigens during therapy [92].

CONCLUSION

For treating numerous diseases of eyes, there are some major limitations that standard eye drops got to face: they need to be applied on regular basis, their bioavailability is kind of low and that they are extremely exposed to general area. Well tolerated systems are designed up that consolidate the continued discharge properties of inserts aboard the adequacy of the patients for typical eye drops. The speed of disintegration/bioerosion of the materials because of nanoparticles among the consideration drops will be adequately controlled which they're very much endured. An importance promise is to manage for ophthalmic conveyance of drug by plan of harming polymers as blend frameworks [93]. blend of systems is right for medication that are insufficiently water solvent and thinks about drop-wise organization adjacent to keeping up the movement of the medicine at focus on objective. Besides, to accommodate an enormous reasonably active, surface-modified nanoparticulate carriers area unit used. on these lines, promising drug carriers are shown by nanoparticles for the ophthalmic applications. once most binding to those particles, the retention of the medication at intervals is considerably enlarged once contrasted with the attention drop solutions, transportation with reference to slower elimination rate of the particles. Smaller sized particles area unit higher endured by the patients once place next with the particles larger in size, thus, nanoparticles can indicate really cozy ophthalmic extended action delivery systems. even though nanoparticles have resulted to be a boon for the ocular drug delivery system, however still there are some challenges to be long-faced within the coming future. the most biological process issues associated with nanoparticles include particle size uniformity, formulation stability, massive scale manufacture of sterile preparations and management of drug release rat [94]. Nanoparticles as factor carriers or medication don't have any impact on iris, cornea and retina. any observation is needed for the analysis of biological effects. although various drug loading techniques and artificial techniques area unit informed to be consistent and safe, no methodology has nonetheless been standardized for the formulation of drug-loaded nanoparticles. Long incubation time and warming is required for nanomedicine gain gold nanoparticles [95]. Fusing high measure of DNA with the nanoparticles likely could be an astounding test for factor its delivery [96]. The

sense of surrounding created by solvent nanoparticles and furthermore the outside of insoluble particles may interfere with the biological systems [97]. change of same set up of nanomaterials is required. Focusing on testing the mixes of extra substances in order to support reasonable properties got the chance to be cleared out future. Clinical headway is endless and it'll be challenging to check the advantages that these inventive prescriptions may supply to the patients [98,99].

ACKNOWLEDGEMENT

The Authors would like to acknowledge Chitkara University and Chitkara College of pharmacy for providing the infrastructure and technical support.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.

REFERENCE

- Diebold, Y., Calonge, M. Applications of nanoparticles in ophthalmology. *Prog Retin Eye Res.* 2010; 9(6):596-609.
- Kesavan, K., Balasubramaniam, J., Kant, S., Singh, P.N., Pandit, J.K. Newer approaches for optimal bioavailability of ocularly delivered drugs: review. *Curr Drug Deliv.* 2011; 8:172-193.
- Ammar, H.O., Salama, H.A., Ghorab, M., Mahmoud, A.A. Nano emulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. *AAPS Pharm Sci Tech.* 2009; 10:808-819.
- Lofts son, T., Duchene, D. Cyclodextrins and their pharmaceutical applications. *Int J Pharm.* 2007; 329:1-11.
- Guinedi, A.S., Mortada, N.D., Mansour, S., Hathout, R.M. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. *Int J Pharm.* 2005; 306:71-82.
- Bourlais, C.L., Acar, L., Zia, H., Sado, P.A., Needham, T., Leverage, R. Ophthalmic drug delivery systems-recent advances. *Prog Retin Eye Res.* 1998; 17:33-58.
- Kayser, O., Lemke, A., Hernandez-Trejo, N. The impact of Nano biotechnology on the development of new drug delivery systems. *Curr Pharm Biotechnol.* 2005; 6:3-5.
- Vieira, D.B., Gamarra, L.F. Advances in the use of nanocarriers for cancer diagnosis and treatment. Einstein (Sao Paulo). 2016; 14(1):99-103.
- Sultana, Y., Powell, M.P., Molock, F.F., Martin, A.W., Jain, R., Aqill, M. Review of ocular drug delivery. *Curr Drug Deliv.* 2006; 3:207-217.
- Vandervoort, J., Ludwig, A. Ocular drug delivery: nanomedicine applications. *Nano med.* 2007; 2:11-21.
- Henderly, D.E., Freeman, W.R., Henderly, D.E., Wan, W.L. Cytomegalovirus retinitis and response to therapy with ganciclovir. *Ophthalmol.* 1987; 94:425-434.
- Anand, R., Sanborn, G.E., Torti, R.E. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. *Arch Ophthalmol.* 1993; 111:223-227.
- Charles, N.C., Steiner, G.C. Ganciclovir intraocular implant: A clinicopathologic Study. *Ophthalmol.* 1996; 103:416-421.
- Engstrom, R.E., et al. Local therapy for cytomegalovirus retinopathy. *Am J Ophthalmol.* 1995; 120:376-385.
- Dunn, J.P., Van Natta, M., Foster, G. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: The Ganciclovir cidofovir cytomegalovirus retinitis trial. *Retina.* 2004; 24:41-50.
- Martin, D.F., Sierra-Madero, J., Walmsley, S. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society – USA panel. *Am J Ophthalmol.* 1999; 127:329-339.
- Musch, D.C., Martin, D.F., Gordon, J.F., Davis, M.D., Kuppermann, B.D. Treatment of cytomegalovirus retinitis with a sustained release ganciclovir implant. The Ganciclovir Implant Study Group. *N Engl J Med.* 1997; 337:83-90.
- Sanborn, G.E., Anand, R., Torti, R.E. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. *Arch Ophthalmol.* 1992; 110:188-195.
- Irache, J.M., Merodio, M., Arnedo, A. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. *Mini Rev Med Chem.* 2005; 5:293-305.
- Vandamme, T.F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. *Prog Retin Eye Res.* 2002; 21:15-34.
- Lawrence, M.J., et al. Microemulsion-based media as novel drug delivery systems. *Adv Drug Deliv.* 2000; 45:89-121.
- Marchal-Heussler, L., Maincent, P., Hoffman, M., Sirbat, D. Value of the new drug carriers in ophthalmology: liposomes and nanoparticles. *J Fr Ophthalmol.* 1990; 13:575-582.
- Bourges, J.L., Gautier, S.E., Delie, F., Bejjani, R.A., Jeanny, J.C., Gurny, R., BenEzra, D. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. *Invest Ophthalmol Vis Sci.* 2003; 44:3562-3569.
- Li, V.H., Wood, R.W., Kreuter, J., Harmia, T., Robinson, J.R. Ocular drug delivery of progesterone using nanoparticles. *J Microencapsul.* 1986; 3:213-218.
- Bochot, A., Fattal, E., Boutet, V. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. *Invest Ophthalmol Vis Sci.* 2002; 43:253-259.
- Perini, G., et al. Niosomes as carriers for ophthalmic drugs: in vitro/in vivo evaluation. *Boll Chim Farm.* 1996; 135:145-146.
- Kaur, I.P., Garg, A., Singla, A.K., Aggarwal, D. Vesicular systems in ocular drug delivery: an overview. *Int J Pharm.* 2004; 269:1-14.
- Aggarwal, D., Kaur, I.P. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. *J Pharm Pharmacol.* 2004; 56:1509-1517.
- Quintana, A., Raczka, E., Piehler, L., Lee, I. et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. *Pharm Res.* 2002; 19:1310-1316.
- De Jesus, O.L.D., Ihre, H.R., Gagne, L., Fréchet, J.M.J., Szoka, Jr. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. *Bioconjug Chem.* 2002; 13:453-461.
- Ihre, H.R., Padilla De Jesus, O.L., Szoka Jr., F.C., Fréchet, J.M.J. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. *Bioconjug Chem.* 2002; 13:443-452.
- Patton, T.F., Robinson, J.R. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. *J Pharm Sci.* 1975; 64:1312-16.
- Aktas, Y., Unlu Norhan, M., Irkeç, M., Hincal, A.A. Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine. *Drug Dev Ind Pharm.* 2003; 29:223-230.
- Loftsson, T., Jarho, P., Måsson, M., Järvinen, T. Cyclodextrins in drug delivery. *Exp Opin Drug Deliv.* 2005; 2:335-351.
- McNamara, N.A., Polse, K.A., Brand, R.J., Graham, A.D., Chan, J.S., McKenney, C.D. Tear mixing under a soft contact lens: effects of lens diameter. *Am J Ophthalmol.* 1999; 127:659-665.
- Kompella, U.B., Kadam, R.S., Lee, V.H. Recent advances in ophthalmic drug delivery. *Ther Deliv.* 2010; 1:435-456.
- Wei, G., Xu, H., Ding, P.T., Li, S.M., Zheng, J.M. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. *J Control Release.* 2002; 83:65-74.
- Loftsson, T., Duchene, D. Cyclodextrins and their pharmaceutical applications. *Int J Pharm.* 2007; 329:1-11.
- Leonardi, A., Bucolo, C., Drago, F., Salomone, S., Pignatello, R. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. *Int J Pharm.* 2015; 478:180-186.
- Pan, Q., Xu, Q., Boylan, N, J., Lamb, N., et al. Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats. *J Control Release.* 2015; 201:32-40.
- Hermans, K., Plas, D.V., Schreurs, E., et al. Cytotoxicity and anti-inflammatory activity of cyclosporine A loaded PLGA nanoparticles for ocular use. *Pharmazie.* 2014; 69:32-37.
- Cholkar, K., Hariharan, S., Gunda, S., Mitra, A.K. Optimization of Dexamethasone Mixed Nanomicellar Formulation. *AAPS J.* 2014; 6:1454-1467.

43. Nagai, N., Yoshioka, C., Mano, Y., *et al.* A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure. *Exp Eye Res.* 2015; 132:115-123.
44. Katzer, T., Chaves, P., Bernardi, A., Pohlmann, A., Guterres, S.S., Ruver Beck, R.C. Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. *J Microencapsul.* 2014; 31:519-528.
45. Moya-Ortega, M.D., Alves, T.F.G., Lorenzo, C.A., Concheiro, A., Stefánsson, E., Thorsteinsdóttir, M., Loftsson, T. Dexamethasone eye drops containing cyclodextrin-based nanogels. *Int J Pharm.* 2013; 441:507-515.
46. Nagai, N., Ito, Y., Okamoto, N., Shimomura, Y. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. *Toxicol.* 2014; 319:53-62.
47. Nagai, N., Ono, H., Hashino, M., Okamoto, N., *et al.* Improved corneal toxicity and permeability of Trnilast by the preparation of Ophthalmic formulations containing its nanoparticles. *J Oleo Sci.* 2014; 63:177-186.
48. Chandasana, H., Prasad, Y.D., Chhonker, Y.S., *et al.* Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: An approach to reduce dose and dosing frequency. *Int J Pharm.* 2014; 477:317-25.
49. Baba, K., Tanaka, Y., Kubota, A., *et al.* A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolysable dye. *J Control Release.* 2011; 153:278-87.
50. Johannesson, G., Moya-Ortega, M.D. A' sgrn' msdo' ttir GM, *et al.* Kinetics of c-cyclodextrin nanoparticle suspension eye drops in tear fluid. *Acta Ophthalmol.* 2013; 54:1385.
51. Jóhannsdóttir, S., Jansook, P., Stefánsson, E., Loftsson, T. Development of a cyclodextrin-based aqueous cyclosporine eye drop formulations. *Int J Pharm.* 2015; 493:86-95.
52. Asasutjarit, R., Theerachayanan, T., Kewsuwan, P., *et al.* Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use. *AAPS J.* 2015; 16:1013-1024.
53. Kesarla, R., Tank, T., Vora, P.A., Shah, T., Parmar, S., Omri, A. Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel. *Drug Deliv.* 23:2363-2370.
54. Lajunen, T., Hisazumi, K., Kanazawa, T., *et al.* Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes. *Eur J Pharm Sci.* 2011; 62:23-32.
55. Lou, J., Hu, W., Tian, R., *et al.* Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles. *Int J Nanomed.* 2014; 9:2517-2525.
56. Johannesson, G., Moya-Ortega, M.D., Asgrímsdóttir, G.M., *et al.* Dorzolamide Cyclodextrin Nanoparticle Suspension Eye Drops and Trusopt in Rabbit. *J Ocul Pharmacol Ther.* 2014; 30:464-467.
57. Ibrahim, M.M., Abd-Elgawad, A.H., Soliman, O.A., *et al.* Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma. *Transl Vis Sci Technol.* 2015; 4:1-13.
58. Gupta, H., Aqil, M., Khar, R.K., Ali, A., Bhatnagar, A., Mittal, G. Nanoparticles laden in situ gel for sustained ocular drug delivery. *J Pharm Bioall Sci.* 2013; 5:162-165.
59. Li, J., Wu, L., Wu, W., *et al.* A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. *Int J Pharm.* 2013; 455:1-2.
60. Khutoryanskaya, O.V., Morrison, P.W.J., Seilkhanov, S.K., *et al.* Hydrogen-Bonded Complexes and Blends of Poly (acrylic acid) and Methylcellulose: Nanoparticles and Mucoadhesive Films for Ocular Delivery of Riboflavin. *Macromol Biosci.* 2014; 14:225-234.
61. Silva, S.B., Ferreira, D., Pintado, M., Sarmento, B. Chitosan-based nanoparticles for rosmarinic acid ocular delivery - in vitro tests. *Int J Bio Macromolec.* 2015; 84:112-120.
62. Ibrahim, M.M., Abd-Elgawad, A.H., Soliman, O.A., *et al.* Novel Topical Ophthalmic Formulations for Management of Glaucoma. *Pharm Res.* 2013; 30:2818-2831.
63. Li, J., Guo, X., Liu, Z., *et al.* Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. *Drug Dev Ind Pharm.* 2014; 40:980-987.
64. Ibrahim, M.M., Abd-elgawad, A.H., Soliman, O.A., Jablonski, M.M. Pharmaceutical Nanotechnology Nanoparticle-Based Topical Ophthalmic Formulations for Sustained Celecoxib Release. *J Pharm Sci.* 2013; 102:1036-1053.
65. Abdelbary, G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. *Pharm Dev Technol.* 2011; 16:44-56.
66. Tommaso, C.D., Torriglia, A., Furrer, P., Behar-Cohen, F., Gurny, R., Möller, M. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly (ethylene glycol)-hexyl substituted poly(lactide) micelle carriers. *Int J Pharm.* 2011; 416:515-524.
67. Kalam, M.A., Sultana, Y., Ali, A., *et al.* Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. *J Biomed Mater Res Part A.* 2013; 101A:1828-1836.
68. Tayel, S.A., El-Nabarawi, M.A., Tadros, M.I., Abd-Elsalam, W.H. Positively Charged Polymeric Nanoparticle Reservoirs of Terbinafine Hydrochloride: Preclinical Implications for Controlled Drug Delivery in the Aqueous Humor of Rabbits. *Pharm. Sci Tech.* 2013; 14:782-793.
69. Baig, M.S., Ahad, A., Aslam, M., Imam, S.S., Aquil, M., Ali, A. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity. *Int J Biol Macromolec.* 2016; 85:258-270.
70. Rafie, F., Javadzadeh, Y., Ali, R., Javadzadeh, A.R., *et al.* In Vivo Evaluation of Novel Nanoparticles Containing Dexamethasone for Ocular Drug Delivery on Rabbit Eye. *Curr Eye Res.* 2010; 35:1081-1089.
71. Agarwal, R.C., Kumar, R., Pandit, J.K. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro characterization and in vivo study in rabbit eye. *Eur J Pharm Sci.* 2012; 47:678-685.
72. Jung, H.J., Chauhan, A. Extended Release of Timolol from Nanoparticle-Loaded Fornix Insert for Glaucoma Therapy. *J Ocul Pharmacol Ther.* 2013; 29:229-235.
73. Kaur, I.P., Kanwar, M. Ocular preparations: the formulation approach. *Drug Dev Ind Pharm.* 2002; 28:473-493.
74. Saettoni, M.F., Chetoni, P., Cerbai, R., *et al.* Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four P-blockers and in vitro/in vivo toxic activity. *Int J Pharm.* 1996; 142:103-113.
75. De Campos, A.M., Sanchez, A., Alonso, M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. *Int J Pharm.* 2001; 224:159-168.
76. Losa, C., Calvo, P., Castro, E., Vila-Jato, J.L., Alonso, M.J. Improvement of ocular penetration of amikacin sulphate by association to poly (butyl cyanoacrylate) nanoparticles. *J Pharm Pharmacol.* 1991; 43:548-552.
77. Chaiyasan, W., Srinivas, S.P., Tiyaboonchai, W. Mucoadhesive chitosan-dextran sulfate nanoparticles for sustained drug delivery to the ocular surface. *J Ocul Pharmacol Ther.* 2013; 29:200-207.
78. Fuente, D.M., Seijo, B., Alonso, M.J. Bio adhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. *Gene Ther.* 2008; 15:668-676.
79. Wood, R.W., Li, V.H.K., Kreuter, Robinson, J.R. Ocular disposition of poly-hexyl-2-cyano [3-14C] acrylate nanoparticles in the albino rabbit. *Int J Pharm.* 1985; 23:175-183.
80. Legen, I., Kracun, M., Salobir, M., Kerc, J. The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin. *Int J Pharm.* 2003; 308:84-89.
81. Smith, J., Wood, E., Dornish, M. Effect of chitosan on epithelial cell tight junctions. *Pharm Res.* 2004; 21:43-49.
82. Zhang, X.N., Xu, J., Tang, L.H., *et al.* Influence on intestinal mucosa permeation of paclitaxel of absorption enhancers and dosage forms based on electron spin resonance spectroscopy. *Pharmazie.* 2007; 62:368-371.
83. Kim, J.W., Lindsey, J.D., Wang, N., Weinreb, R.N. Increased human scleral permeability with prostaglandin exposure. *Invest. Ophthalmol. Vis Sci.* 2001; 42:1514-1521.
84. Sasaki, H., Igarashi, Y., Nagano, T., Nishida, K., Nakamura, J. Different Effects of Absorption Promoters on Corneal and Conjunctival Penetration of Ophthalmic Beta-Blockers. *Pharm Res.* 1996; 12:1146-1150.

85. Green, K., Tonjum, A.M. The effect of benzalkonium chloride on the electro potential of the rabbit cornea. *Acta Ophthalmol (Copenh)*. 1975; 53:348-357.
86. Williams, A.C., Barry, B.W. Penetration enhancers. *Adv Drug Deliv Rev*. 2004; 56:603-618.
87. Grass, G.M., Wood, R.W., Robinson, J.R. Effects of calcium chelating agents on corneal permeability. *Invest Ophthalmol Vis Sci*. 1985; 26:110-13.
88. Rojanasakul, Y., Liaw, J., Robinson, J.R. Mechanisms of action of some penetration enhancers in the cornea: Laser scanning confocal microscopic and electrophysiology studies. *Int J Pharm*. 1990; 66:131-142.
89. Prow, T.W., Bhutto, I., Kim, S.Y., *et al*. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. *Nanomed*. 2008; 4:340-49.
90. Kannan, S., Dai, H., Navath, R.S., *et al*. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. *Sci Transl Med*. 2012; 4:130-146.
91. Marano, R.J., Toth, I., Wimmer, N., Brankov, M., Rakoczy, P.E. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. *Gene Ther*. 2005; 12:1544-1550.
92. Ding, X.Q., Quiambao, A.B., Fitzgerald, J.B., Conley, S.M., Naash, M.I. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. *PLoS One*. 2009; 4:7410.
93. Ambade, A.V., Savariar, E.N., Thayumanavan, S. Dendrimeric micelles for controlled drug release and targeted delivery. *Mol Pharmacol*. 2005; 2:264-272.
94. Mainardes, R.M., Urban, M.C.C., *et al*. Colloidal Carriers for Ophthalmic Drug Delivery. *Curr Drug Targets*. 2005; 6:363-371.
95. Cordray, M.S., Amdahl, M., Richards-Kortum, R.R. Gold nanoparticle aggregation for quantification of oligonucleotides: Optimization and increased dynamic range. *Anal Biochem*. 2012; 431:99-105.
96. Pannier, A.K., Segura, T. Surface and hydrogel-mediated delivery of nucleic Acid NPs. *Methods Mol Biol*. 2013; 948:149-169.
97. Donaldson, K., Schinwald, A., Murphy, F. The biologically effective dose in inhalation nanotoxicology. *Acc Chem Res*. 2012; 46(3):723-732.
98. Arora, M., Chan, E.K., Gupta, S., Diwan, A.D. Polymethylmethacrylate bone cements and additives: A review of the literature. *World J Orthop*. 2013; 4:67-74.
99. Heidel, J.D., Schlupe, T. Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. *J Drug Deliv*. 2012; 262-731.